| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 157, Issue 6 2521-2527, Copyright © 1996 by American Association of Immunologists
ARTICLES |
LS Klavinskis, LA Bergmeier, L Gao, E Mitchell, RG Ward, G Layton, R Brookes, NJ Meyers and T Lehner
Department of Immunology, United Medical and Dental Schools of Guy's and St. Thomas' Hospital, London, United Kingdom.
The major routes of HIV transmission are through the rectal and cervico- vaginal mucosa. To prevent dissemination of HIV to the regional lymph nodes (LNs), an effective vaccine may need to stimulate CTL in the rectal or genital tract and the draining LNs. We report that mucosal immunization by the recto-oral and vagino-oral route or s.c. immunization targeting the iliac LNs with a particulate SIVp27:Ty-VLP vaccine elicits SIVgag-specific CTL in the regional LNs as well as in the spleen and PBMC. Targeted LN immunization with this vaccine elicited MHC class I-restricted CD8+ CTL responses, and the highest frequency of CTL was found in the iliac LNs. Moreover, SIVgag-specific CTL activity was detected in short term T cell lines established in mononuclear cells eluted from the rectal and cervico-vaginal mucosa. The relative frequency of CTL in short term cell lines prepared from the rectal mucosa (21/113 or 18.6%) was similar to that obtained from the cervico-vaginal mucosa (16/79 or 20.3%). Examination of the relative frequency of CTL to the T cell epitopes residing within SIVp27 showed a higher frequency in iliac LN cells to peptide aa 41-70 than in that to peptide aa 121-150, and this was significant after both recto- oral (chi-squared 6.500, p < 0.02) and vagino-oral (chi-squared = 10.391, p < 0.01) immunization. In contrast, the relative frequency of CTL in PBMC to peptide aa 41-70 (15.5%) was comparable to that elicited by peptide aa 121-150 (17.6%). This study provides novel evidence that mucosal or targeted LN immunization can generate anti-SIV CTL in the rectal and genital mucosa, in the draining LNs, and in the central lymphoid system.
This article has been cited by other articles:
|
|
 |
|
  N. Larke, A. Murphy, C. Wirblich, D. Teoh, M. J. Estcourt, A. J. McMichael, P. Roy, and T. Hanke Induction of Human Immunodeficiency Virus Type 1-Specific T Cells by a Bluetongue Virus Tubule-Vectored Vaccine Prime-Recombinant Modified Virus Ankara Boost Regimen J. Virol., December 1, 2005; 79(23): 14822 - 14833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, R. Fayad, X. Wang, D. Quinn, and L. Qiao Human Immunodeficiency Virus Type 1 Gag-Specific Mucosal Immunity after Oral Immunization with Papillomavirus Pseudoviruses Encoding Gag J. Virol., October 1, 2004; 78(19): 10249 - 10257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. M. Negri, S. Baroncelli, S. Catone, A. Comini, Z. Michelini, M. T. Maggiorella, L. Sernicola, F. Crostarosa, R. Belli, M. G. Mancini, et al. Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge J. Gen. Virol., May 1, 2004; 85(5): 1191 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. N. Bertley, P. A. Kozlowski, S.-W. Wang, J. Chappelle, J. Patel, O. Sonuyi, G. Mazzara, D. Montefiori, A. Carville, K. G. Mansfield, et al. Control of Simian/Human Immunodeficiency Virus Viremia and Disease Progression after IL-2-Augmented DNA-Modified Vaccinia Virus Ankara Nasal Vaccination in Nonhuman Primates J. Immunol., March 15, 2004; 172(6): 3745 - 3757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Shacklett, C. A. Cox, J. K. Sandberg, N. H. Stollman, M. A. Jacobson, and D. F. Nixon Trafficking of Human Immunodeficiency Virus Type 1-Specific CD8+ T Cells to Gut-Associated Lymphoid Tissue during Chronic Infection J. Virol., May 15, 2003; 77(10): 5621 - 5631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Peters, X. Peng, D. Douven, Z.-K. Pan, and Y. Paterson The Induction of HIV Gag-Specific CD8+ T Cells in the Spleen and Gut-Associated Lymphoid Tissue by Parenteral or Mucosal Immunization with Recombinant Listeria monocytogenes HIV Gag J. Immunol., May 15, 2003; 170(10): 5176 - 5187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Malkevitch, L. J. Patterson, K. Aldrich, E. Richardson, W. G. Alvord, and M. Robert-Guroff A Replication Competent Adenovirus 5 Host Range Mutant-Simian Immunodeficiency Virus (SIV) Recombinant Priming/Subunit Protein Boosting Vaccine Regimen Induces Broad, Persistent SIV-Specific Cellular Immunity to Dominant and Subdominant Epitopes in Mamu-A*01 Rhesus Macaques J. Immunol., April 15, 2003; 170(8): 4281 - 4289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Stevceva, B. Kelsall, J. Nacsa, M. Moniuszko, Z. Hel, E. Tryniszewska, and G. Franchini Cervicovaginal Lamina Propria Lymphocytes: Phenotypic Characterization and Their Importance in Cytotoxic T-Lymphocyte Responses to Simian Immunodeficiency Virus SIVmac251 J. Virol., January 1, 2002; 76(1): 9 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Rayevskaya and F. R. Frankel Systemic Immunity and Mucosal Immunity Are Induced against Human Immunodeficiency Virus Gag Protein in Mice by a New Hyperattenuated Strain of Listeria monocytogenes J. Virol., March 15, 2001; 75(6): 2786 - 2791. [Abstract] [Full Text]
|
|
|
|
|
|
S.-W. Wang, P. A. Kozlowski, G. Schmelz, K. Manson, M. S. Wyand, R. Glickman, D. Montefiori, J. D. Lifson, R. P. Johnson, M. R. Neutra, et al. Effective Induction of Simian Immunodeficiency Virus-Specific Systemic and Mucosal Immune Responses in Primates by Vaccination with Proviral DNA Producing Intact but Noninfectious Virions J. Virol., November 15, 2000; 74(22): 10514 - 10522. [Abstract] [Full Text]
|
|
|
|
|
|
C. Dupuy, D. Buzoni-Gatel, A. Touze, D. Bout, and P. Coursaget Nasal Immunization of Mice with Human Papillomavirus Type 16 (HPV-16) Virus-Like Particles or with the HPV-16 L1 Gene Elicits Specific Cytotoxic T Lymphocytes in Vaginal Draining Lymph Nodes J. Virol., November 1, 1999; 73(11): 9063 - 9071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Klavinskis, C. Barnfield, L. Gao, and S. Parker Intranasal Immunization with Plasmid DNA-Lipid Complexes Elicits Mucosal Immunity in the Female Genital and Rectal Tracts J. Immunol., January 1, 1999; 162(1): 254 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sasaki, K. Sumino, K. Hamajima, J. Fukushima, N. Ishii, S. Kawamoto, H. Mohri, C. R. Kensil, and K. Okuda Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency Virus Type 1 by a DNA Vaccine Formulated with QS-21 Saponin Adjuvant via Intramuscular and Intranasal Routes J. Virol., June 1, 1998; 72(6): 4931 - 4939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Belyakov, M. A. Derby, J. D. Ahlers, B. L. Kelsall, P. Earl, B. Moss, W. Strober, and J. A. Berzofsky Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge PNAS, February 17, 1998; 95(4): 1709 - 1714. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
